Elizabeth S Gebler-Hughes1, Linda Kemp1, Malcolm J Bond2. 1. School of Medicine, Flinders University, Adelaide, SA, Australia. 2. School of Medicine, Health Sciences Building, Flinders University, GPO Box 2100, Adelaide, SA 5001, Australia.
Abstract
OBJECTIVES: To examine patients' perspectives regarding long-term vitamin K antagonist (VKA) therapy and the potential transition to new oral anticoagulants (NOACs) such as dabigatran and rivaroxaban, and to determine if factors such as residential location affect these opinions. DESIGN SETTING AND PARTICIPANTS: Patients on VKA therapy for at least 12 weeks completed a questionnaire specifically designed for the study. They were recruited while attending point-of-care international normalized ratio (INR) testing at six South Australian general practice clinics during the period July-September 2013. MAIN OUTCOME MEASURES: Opinions of current VKA therapy, level of awareness of NOACs, and ratings of potential benefits and deterrents of transition to NOACs were sought. RESULTS: Data from 290 participants were available for analysis (response rate 95.4%). The majority of the sample (79.5%, 229/288) were either satisfied or very satisfied with current VKA therapy. The mean score for the potential benefits of transition to NOACs was 7.6 (±4.2) out of a possible 20, which was significantly lower than the mean score 10.9 (±4.5) for the perceived deterrents to transition (p < 0.001). Rural patients (82.0%, 82/100) were significantly more likely (p = 0.001) to have not heard of NOACs than metropolitan patients (50.3%, 95/189) and also perceived significant less benefits in a transition to NOACs (p = 0.001). CONCLUSION: When considering potential transition from VKAs to NOACs it is important for prescribers to consider that some patients, in particular those from a rural location, may not perceive a significant benefit in transitioning or may have particular concerns in this area.
OBJECTIVES: To examine patients' perspectives regarding long-term vitamin K antagonist (VKA) therapy and the potential transition to new oral anticoagulants (NOACs) such as dabigatran and rivaroxaban, and to determine if factors such as residential location affect these opinions. DESIGN SETTING AND PARTICIPANTS: Patients on VKA therapy for at least 12 weeks completed a questionnaire specifically designed for the study. They were recruited while attending point-of-care international normalized ratio (INR) testing at six South Australian general practice clinics during the period July-September 2013. MAIN OUTCOME MEASURES: Opinions of current VKA therapy, level of awareness of NOACs, and ratings of potential benefits and deterrents of transition to NOACs were sought. RESULTS: Data from 290 participants were available for analysis (response rate 95.4%). The majority of the sample (79.5%, 229/288) were either satisfied or very satisfied with current VKA therapy. The mean score for the potential benefits of transition to NOACs was 7.6 (±4.2) out of a possible 20, which was significantly lower than the mean score 10.9 (±4.5) for the perceived deterrents to transition (p < 0.001). Rural patients (82.0%, 82/100) were significantly more likely (p = 0.001) to have not heard of NOACs than metropolitan patients (50.3%, 95/189) and also perceived significant less benefits in a transition to NOACs (p = 0.001). CONCLUSION: When considering potential transition from VKAs to NOACs it is important for prescribers to consider that some patients, in particular those from a rural location, may not perceive a significant benefit in transitioning or may have particular concerns in this area.
Entities:
Keywords:
INR; Warfarin; oral anticoagulants; patient preferences; vitamin K antagonists
Authors: Megan B Smith; Nedra Christensen; Shiquan Wang; Jennifer Strohecker; John D Day; J Peter Weiss; Brian G Crandall; Jeffrey S Osborn; Jeffrey L Anderson; Benjamin D Horne; Joseph B Muhlestein; Donald L Lappe; Heidi Moss; Jessica Oliver; Krista Viau; T Jared Bunch Journal: Cardiology Date: 2010-05-26 Impact factor: 1.869
Authors: Walter Ageno; Alexander S Gallus; Ann Wittkowsky; Mark Crowther; Elaine M Hylek; Gualtiero Palareti Journal: Chest Date: 2012-02 Impact factor: 9.410
Authors: Renato D Lopes; John H Alexander; Sana M Al-Khatib; Jack Ansell; Raphael Diaz; J Donald Easton; Bernard J Gersh; Christopher B Granger; Michael Hanna; John Horowitz; Elaine M Hylek; John J V McMurray; Freek W A Verheugt; Lars Wallentin Journal: Am Heart J Date: 2010-03 Impact factor: 4.749
Authors: Stuart J Connolly; Michael D Ezekowitz; Salim Yusuf; John Eikelboom; Jonas Oldgren; Amit Parekh; Janice Pogue; Paul A Reilly; Ellison Themeles; Jeanne Varrone; Susan Wang; Marco Alings; Denis Xavier; Jun Zhu; Rafael Diaz; Basil S Lewis; Harald Darius; Hans-Christoph Diener; Campbell D Joyner; Lars Wallentin Journal: N Engl J Med Date: 2009-08-30 Impact factor: 91.245